Skip to content

Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates

Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02235766
Acronym
CORELAB-CRT
Enrollment
50
Registered
2014-09-10
Start date
2015-03-31
Completion date
2017-06-30
Last updated
2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Cardiac Resynchronization Therapy, Satellite Tele-Echocardiography

Brief summary

Purpose of the observational study is to assess the capability of a satellite tele-echocardiography (STE) system to acquire and transmit echocardiographic images and clips to an echocardiographic core laboratory (ECL) in a real time mode without loss of quality. Additionally the prognostic efficacy of specific echo parameters in the cardiac resynchronization therapy response will be evaluated.

Detailed description

CORELAB-CRT is a prospective multi center Italian observational study. All echo images and clips will be transmitted by using an integrated satellite transmission system. All echo assessments performed in accordance to the centers clinical practice will be also used to investigate the prognostic efficacy of echo parameters in term of response to the cardiac resynchronization therapy (CRT). All commercially available multi-chamber CRT-D devices from any manufacturers are allowed in this observational study. Any compatible market released right atrial, right ventricular and left ventricular lead from any manufacturer is allowed. The echocardiography device models used to perform echo imaging for all patients participating in this analysis are GE Vivid 7, GE Vivid 9 and GE Vivid I, according to the model used in the clinical practice of the hospital.

Interventions

Sponsors

Kell s.r.l.
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. NYHA class II, III and ambulatory IV with: * QRS complex duration ≥120msec; * Ejection fraction ≤35%. 2. Optimized medical treatment; 3. Patient in sinus rhythm; 4. Patient is willing and able to sign an informed consent form.

Exclusion criteria

1. Unstable angina, or acute myocardial infarction, coronary-aortic bypass graft or percutaneous transluminal coronary angioplasty within the past 3 months; 2. Cerebral vascular attacks or transient ischemic attack within the last month; 3. Chronic atrial arrhythmias, paroxysmal atrial fibrillation events; 4. Patients already implanted with an ICD or a CRT device; 5. Pacemaker dependency or ventricular pacing percentage ≥10%; 6. Valvular disease with an indication for surgical correction ≤12 months survival expectancy; 7. Mechanical right ventricular valve; 8. Patient is enrolled in or intends to participate in another clinical trial that may have an impact on the study endpoints; 9. Pregnancy or breastfeeding; 10. Previous heart transplant; 11. Refusal of study informed consent; 12. Expected lack of compliance during follow-up; 13. Patient is less than 18 years of age; 14. Patient's life expectancy is less than 6 months in the opinion of physician.

Design outcomes

Primary

MeasureTime frameDescription
ECM assessment6 monthsAgreement in the echocardiographic measurement capability (EMC) between transmitted and echocardiographic device image on the set of high quality images transmitted by STE. Each echo image will be classified as high quality image if the Mean Opinion Score (MOS) will be greater than 3 points. For each high quality echo image (MOS greater or equal 3) the EMC will be assessed to both transmitted and device echocardiographic image.

Secondary

MeasureTime frameDescription
Prognostic efficacy of specific echo parameters6 monthsEchocardiographic response defined as LVESV reduction ≥10% at 6 months after CRT-D implantation.
Clinical composite score CCS6 monthsCCS describing patients regardless of vital status at 6 months and includes both objective and subjective measures of clinical status.

Countries

Italy

Contacts

Primary ContactCesare Aragno
caragno@kell.it+39 06 36004916

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026